288 related articles for article (PubMed ID: 16442912)
1. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function.
Ahmed A; Aronow WS; Fleg JL
Am Heart J; 2006 Feb; 151(2):444-50. PubMed ID: 16442912
[TBL] [Abstract][Full Text] [Related]
2. A propensity-matched study of the association of physical function and outcomes in geriatric heart failure.
Ahmed A; Aronow WS
Arch Gerontol Geriatr; 2008; 46(2):161-72. PubMed ID: 17532064
[TBL] [Abstract][Full Text] [Related]
3. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
[TBL] [Abstract][Full Text] [Related]
4. A propensity matched study of New York Heart Association class and natural history end points in heart failure.
Ahmed A
Am J Cardiol; 2007 Feb; 99(4):549-53. PubMed ID: 17293201
[TBL] [Abstract][Full Text] [Related]
5. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure.
Koyama Y; Takeishi Y; Arimoto T; Niizeki T; Shishido T; Takahashi H; Nozaki N; Hirono O; Tsunoda Y; Nitobe J; Watanabe T; Kubota I
J Card Fail; 2007 Apr; 13(3):199-206. PubMed ID: 17448417
[TBL] [Abstract][Full Text] [Related]
6. Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction.
Greene SJ; Butler J; Spertus JA; Hellkamp AS; Vaduganathan M; DeVore AD; Albert NM; Duffy CI; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
JAMA Cardiol; 2021 May; 6(5):522-531. PubMed ID: 33760037
[TBL] [Abstract][Full Text] [Related]
7. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure.
Lindenfeld J; Feldman AM; Saxon L; Boehmer J; Carson P; Ghali JK; Anand I; Singh S; Steinberg JS; Jaski B; DeMarco T; Mann D; Yong P; Galle E; Ecklund F; Bristow M
Circulation; 2007 Jan; 115(2):204-12. PubMed ID: 17190867
[TBL] [Abstract][Full Text] [Related]
8. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.
Pfisterer M; Buser P; Rickli H; Gutmann M; Erne P; Rickenbacher P; Vuillomenet A; Jeker U; Dubach P; Beer H; Yoon SI; Suter T; Osterhues HH; Schieber MM; Hilti P; Schindler R; Brunner-La Rocca HP;
JAMA; 2009 Jan; 301(4):383-92. PubMed ID: 19176440
[TBL] [Abstract][Full Text] [Related]
9. Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy.
Georgiopoulou VV; Kalogeropoulos AP; Giamouzis G; Agha SA; Rashad MA; Waheed S; Laskar S; Smith AL; Butler J
Circ Heart Fail; 2009 Mar; 2(2):90-7. PubMed ID: 19808323
[TBL] [Abstract][Full Text] [Related]
10. Association of New York Heart Association functional class IV symptoms at admission and clinical features with outcomes in patients hospitalized for acute heart failure syndromes.
Asano R; Kajimoto K; Oka T; Sugiura R; Okada H; Kamishima K; Hirata T; Sato N;
Int J Cardiol; 2017 Mar; 230():585-591. PubMed ID: 28057363
[TBL] [Abstract][Full Text] [Related]
11. The effect of digoxin on mortality and morbidity in patients with heart failure.
Digitalis Investigation Group
N Engl J Med; 1997 Feb; 336(8):525-33. PubMed ID: 9036306
[TBL] [Abstract][Full Text] [Related]
12. Sex-based differences in the effect of digoxin for the treatment of heart failure.
Rathore SS; Wang Y; Krumholz HM
N Engl J Med; 2002 Oct; 347(18):1403-11. PubMed ID: 12409542
[TBL] [Abstract][Full Text] [Related]
13. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.
Dhaliwal AS; Bredikis A; Habib G; Carabello BA; Ramasubbu K; Bozkurt B
Am J Cardiol; 2008 Nov; 102(10):1356-60. PubMed ID: 18993155
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).
Wong CM; Hawkins NM; Jhund PS; MacDonald MR; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; McMurray JJ
J Am Coll Cardiol; 2013 Nov; 62(20):1845-54. PubMed ID: 23850914
[TBL] [Abstract][Full Text] [Related]
15. Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial.
Adams KF; Butler J; Patterson JH; Gattis Stough W; Bauman JL; van Veldhuisen DJ; Schwartz TA; Sabbah H; Mackowiak JI; Ventura HO; Ghali JK
Eur J Heart Fail; 2016 Aug; 18(8):1072-81. PubMed ID: 27492641
[TBL] [Abstract][Full Text] [Related]
16. Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial.
Ahmed A; Aronow WS; Fleg JL
Am J Ther; 2006; 13(4):325-31. PubMed ID: 16858168
[TBL] [Abstract][Full Text] [Related]
17. Comparison of morbidity in women versus men with heart failure and preserved ejection fraction.
Deswal A; Bozkurt B
Am J Cardiol; 2006 Apr; 97(8):1228-31. PubMed ID: 16616031
[TBL] [Abstract][Full Text] [Related]
18. Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial.
Ambrosy AP; Bhatt AS; Stebbins AL; Wruck LM; Fudim M; Greene SJ; Kraus WE; O'Connor CM; Piña IL; Whellan DJ; Mentz RJ
Am Heart J; 2018 May; 199():97-104. PubMed ID: 29754673
[TBL] [Abstract][Full Text] [Related]
19. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial.
Gheorghiade M; Patel K; Filippatos G; Anker SD; van Veldhuisen DJ; Cleland JG; Metra M; Aban IB; Greene SJ; Adams KF; McMurray JJ; Ahmed A
Eur J Heart Fail; 2013 May; 15(5):551-9. PubMed ID: 23355060
[TBL] [Abstract][Full Text] [Related]
20. Cardiac resynchronization therapy in patients with systolic left ventricular dysfunction and symptoms of mild heart failure secondary to ischemic or nonischemic cardiomyopathy.
Bleeker GB; Schalij MJ; Holman ER; Steendijk P; van der Wall EE; Bax JJ
Am J Cardiol; 2006 Jul; 98(2):230-5. PubMed ID: 16828599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
